Patients with idiopathic pulmonary fibrosis had less FVC decline between baseline and 26 weeks with receipt of three daily doses of 825 mg deupirfenidone, according to phase 2b ELEVATE IPF trial results.“The efficacy seen with the 825 mg dose of deupirfenidone was certainly better than we dared expect,” Toby M. Maher, MD, PhD, professor of medicine and director of interstitial lung
“.” Annals of the American Thoracic Society, 21(12), pp. 1643–1646 Correspondence and requests for reprints should be addressed to Lynn B. Gerald, Ph.D., M.S.P.H., University…
“.” American Journal of Respiratory Cell and Molecular Biology, 71(6), pp.
“.” American Journal of Respiratory and Critical Care Medicine, 210(12), pp. 1475–1479 Author Contributions: G.D., J.M.S., and H.W. planned the manuscript. A.K. wrote the first…
These resources are for anyone shopping (or helping someone shop) for health coverage within the health insurance marketplaces created through the Affordable Care Act (also…
This brief reviews some of the possible actions of the incoming Trump administration and new Congress based on campaign statements, policies implemented by the first…
A supply-adjusted CAS for lung transplants may lower waitlist mortality and increase transplants in women and others with biological disadvantages.
Tailor your ATS experience! Select which types of ATS news and content you’d like to receive from us. Check your spam filter and mark the…
Key Updates for Week 50, ending December 14, 2024
This interactive feature describes a 44-year-old woman with a 2-year history of shortness of breath with minimal exertion, cough, fatigue, and unintentional weight loss. Test…
The antiviral effect of Paxlovid (nirmatrelvir/ritonavir) is significantly superior to azvudine among inpatients with COVID-19 pneumonia.
